Treatment exposure
myocarditis
MYOCARDITIS
Of the 47 patients, 45 (95.7%) received three cycles of immunotherapy combined with chemotherapy, and two patients (4.3%) discontinued treatment after the second cycle for immune-related myocarditis (n = 1) and informed consent withdrawal (n = 1). Forty-two patients (89.4%) completed surgery as planned. The reasons for not undergoing surgery included patient refusal (n = 4) and immune-related myocarditis (n = 1).